Vincerx Price Earnings Ratio from 2010 to 2024

VINC Stock  USD 0.19  0.01  5.00%   
Vincerx Pharma's Price Earnings Ratio is increasing over the years with slightly volatile fluctuation. Price Earnings Ratio is expected to dwindle to -0.66. During the period from 2010 to 2024 Vincerx Pharma Price Earnings Ratio annual values regression line had coefficient of variation of (72.38) and r-squared of  0.67. View All Fundamentals
 
Price Earnings Ratio  
First Reported
2010-12-31
Previous Quarter
(0.63)
Current Value
(0.66)
Quarterly Volatility
522.91877865
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Vincerx Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vincerx Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 49.4 K, Interest Expense of 8.7 M or Selling General Administrative of 12.9 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.35. Vincerx financial statements analysis is a perfect complement when working with Vincerx Pharma Valuation or Volatility modules.
  
Check out the analysis of Vincerx Pharma Correlation against competitors.
For information on how to trade Vincerx Stock refer to our How to Trade Vincerx Stock guide.

Latest Vincerx Pharma's Price Earnings Ratio Growth Pattern

Below is the plot of the Price Earnings Ratio of Vincerx Pharma over the last few years. It is Vincerx Pharma's Price Earnings Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vincerx Pharma's overall financial position and show how it may be relating to other accounts over time.
Price Earnings Ratio10 Years Trend
Slightly volatile
   Price Earnings Ratio   
       Timeline  

Vincerx Price Earnings Ratio Regression Statistics

Arithmetic Mean(722.42)
Coefficient Of Variation(72.38)
Mean Deviation476.26
Median(1,080)
Standard Deviation522.92
Sample Variance273,444
Range1.1K
R-Value0.82
Mean Square Error96,371
R-Squared0.67
Significance0.0002
Slope95.91
Total Sum of Squares3.8M

Vincerx Price Earnings Ratio History

2024 -0.66
2023 -0.63
2022 -0.38
2021 -11.21
2020 -27.25

About Vincerx Pharma Financial Statements

Vincerx Pharma stakeholders use historical fundamental indicators, such as Vincerx Pharma's Price Earnings Ratio, to determine how well the company is positioned to perform in the future. Although Vincerx Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Vincerx Pharma's assets and liabilities are reflected in the revenues and expenses on Vincerx Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Vincerx Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Price Earnings Ratio(0.63)(0.66)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Vincerx Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vincerx Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vincerx Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vincerx Pharma Stock:
Check out the analysis of Vincerx Pharma Correlation against competitors.
For information on how to trade Vincerx Stock refer to our How to Trade Vincerx Stock guide.
You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vincerx Pharma. If investors know Vincerx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vincerx Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.14)
Return On Assets
(0.66)
Return On Equity
(1.42)
The market value of Vincerx Pharma is measured differently than its book value, which is the value of Vincerx that is recorded on the company's balance sheet. Investors also form their own opinion of Vincerx Pharma's value that differs from its market value or its book value, called intrinsic value, which is Vincerx Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vincerx Pharma's market value can be influenced by many factors that don't directly affect Vincerx Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vincerx Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vincerx Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vincerx Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.